Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics and Safety of Oral Posaconazole (MK-5592)Tablets in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-117)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Chinese participant~* Female of reproductive potential with a serum hCG level consistent with a nongravid state and agree to use 2 acceptable methods of birth control throughout the study~* Body Mass Index (BMI) \>=15 and \<=30 kg/m\^2~* Anticipated or documented prolonged neutropenia and likely to last for at least 7 days due to: a) standard intensive chemotherapy, anthracycline-based or other accepted regimen (excluding any investigational agent) for a new diagnosis of acute myelogenous leukemia (AML); b)chemotherapy for AML in first relapse; or c) therapy for myelodysplastic syndromes in transformation to AML or other diagnoses of secondary AML (therapy related, antecedent hematological disorders) or chronic myelogenous leukemia in blast crisis~* Free from any clinically significant disease other than the primary hematologic disease that would interfere with administration of study medication or study evaluations~Exclusion Criteria:~* Pregnant, intends to become pregnant during the study, or has been nursing~* Mentally or legally incapacitated, has significant emotional problems, or has clinically significant psychiatric disorder over the last 5 years~* Received systemic antifungal therapy (oral, intravenous, or inhaled) within 30 days of study enrollment for reasons other than antifungal prophylaxis~* Known or suspected invasive or systemic fungal infection~* Taken posaconazole within 10 days prior to study enrollment~* Major surgery, donated or lost 1 unit of blood, or participated in another investigational study within 4 weeks prior to the study~* Type 1 hypersensitivity or idiosyncratic reactions to azole agents~* Significant multiple or severe allergies, or has had an anaphylactic reaction or significant intolerability to drugs or food~* Moderate or severe liver dysfunction~* Chronic active hepatitis, cirrhosis, Hepatocellular Carcinoma (HCC), or other hepatic disease caused by a virus~* Previous electrocardiogram with a prolonged QTc interval~* Prior enrollment in this study or other posaconazole studies within 90 days of study entry~* Eastern Cooperative Oncology Group (ECOG) performance status was \>2 prior to induction chemotherapy for the underlying disease~* Known or suspected Gilbert's disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Posaconazole (Type: EXPERIMENTAL): Posaconazole 300 mg tablet (3 x 100 mg tablets) once every 12 hours on Day 1 and once-daily on Days 2 to 28

Based on this trial design, predict the completion outcome and termination type (if applicable).